Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Amphastar Pharmaceuticals, Inc. et al v. Momenta Pharmaceuticals, Inc. et al
Case Number:
1:16-cv-10112
Court:
Nature of Suit:
Judge:
Firms
- Alston & Bird
- Axinn Veltrop
- Boies Schiller
- Chinitz Law
- Choate Hall
- Donnelly Conroy
- Glaser Weil
- Hirsch Roberts Weinstein
- Lipsitz Green
- McDermott Will & Emery
- Michelman & Robinson
- Morrison Foerster
- Shook Hardy
- Wilson Sonsini
Companies
Sectors & Industries:
-
April 06, 2017
Amphastar, Momenta Antitrust Dispute Gets 2019 Trial Date
A federal judge in Boston said Thursday that he would allow Momenta and Sandoz to move again for dismissal in an antitrust dispute with Amphastar over a generic blood-clotting drug, and, depending on how that goes, eyed a tentative trial date two years from now.
-
July 27, 2016
Momenta Wins Dismissal Of Blood-Clot Drug Antitrust Suit
A Massachusetts federal judge on Wednesday said that Amphastar Pharmaceuticals Inc. cannot bring federal antitrust claims against Momenta Pharmaceuticals Inc. for allegedly suppressing competition of sales of a generic blood clot drug because its alleged injury stems from a prior court-issued injunction, immunizing Momenta from suit.
- ← Previous
- 1
- 2
- Next →